Furthermore, the potentials of rosiglitazone and 15d-PGJ2, as well as other PPARγ agonists, in treating PD-associated peritoneal fibrosis deserve further explorations through large-scale clinical trials. Here, PPARG is linked to Peritoneal Fibrosis.